China patented the first Covid-19 vaccine in the country
The Chinese media has
announced that the Covid-19 vaccine, which has not been in phase 3 clinical
trial, called Ad5-nCoV, has been patented.
The Global Times reported
that the newly patented vaccine is a recombinant type called Ad5-nCoV. The
vaccine was developed by CanSino Biopharmaceutical Company (China) in
collaboration with a group led by Chinese military infectious disease expert
Chen Wei.
The Chinese media said that
the patent has confirmed that the vaccine is highly effective and safe, and
proves the intellectual property rights of CanSino. At the same time, it
will increase confidence in the international market with the Covid-19 vaccine
developed by China.
Xu Xinming, an intellectual
property lawyer in Beijing, said that China has a strict and complete patent
inspection system. To be granted a degree, a product or technology must be
fundamentally different from similar products available in the world.
According to Mr. Xu,
CanSino is applying for a patent with foreign authorities to protect
intellectual property rights in the process of international cooperation.
CGTN cites a document
published on the website of the National Intellectual Property Office of China,
saying that the vaccine could be mass produced in a short time when a pandemic
breaks out.
It is known that on March
18, CanSino filed a patent application with the National Intellectual Property
Department. Days ago, they ran a phase one clinical trial on the candidate
and got approval on August 11.
The company said phase 3
vaccine trials have been conducted overseas and have progressed
well. Results of phase one and two tests published on July 20 showed the
vaccine's safety and high level of immunity.
Relevant developments, the
Drug Administration of China recently released documents on the conditions for
Covid-19 vaccines of this country to be approved. Accordingly, the
Covid-19 vaccine which helps at least 50% of the immunized people to be
immunized will be approved and sold on the market.
Having never been there, in
order to get approval, the Covid-19 vaccines from China must also help immunize
the vaccinated person to be immune to the virus for at least 6 months. In
particular, Covid-19 vaccines that meet the efficacy standards will be
immediately approved by China for use in emergencies, despite the lack of
completion of phase 3 - critical phase vaccine testing.
No comments